Waymont B, Lynch T H, Dunn J A, Emtage L A, Arkell D G, Wallace D M, Blackledge G R
CRC Trials Unit, Queen Elizabeth Hospital, Birmingham.
Br J Urol. 1992 Jun;69(6):614-20. doi: 10.1111/j.1464-410x.1992.tb15633.x.
An open randomised Phase III trial was conducted of the depot GnRH analogue goserelin (Zoladex) versus stilboestrol (3 mg/day) in patients with advanced or metastatic prostate cancer. The study included 250 patients and the median follow-up was 43 months. In the Zoladex arm the time to first response was achieved earlier and more patients reported an improvement in symptoms. There was no statistically significant difference between the Zoladex and the stilboestrol arms with regard to survival and time to treatment failure. A major reason for treatment failure was the preponderance of adverse events in patients receiving stilboestrol. It is suggested that stilboestrol should no longer be used for prostate cancer when equally effective alternative treatments are available.
一项开放性随机III期试验对晚期或转移性前列腺癌患者使用长效促性腺激素释放激素类似物戈舍瑞林（诺雷德）与己烯雌酚（3毫克/天）进行了比较。该研究纳入了250名患者，中位随访时间为43个月。在诺雷德组，首次出现反应的时间更早，更多患者报告症状有所改善。在生存和至治疗失败时间方面，诺雷德组和己烯雌酚组之间没有统计学上的显著差异。治疗失败的一个主要原因是接受己烯雌酚治疗的患者中不良事件占多数。建议在有同等有效替代治疗方法时，己烯雌酚不应再用于前列腺癌治疗。
